High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
Simon W JiangJeffery T KwockBeiyu LiuAmy J PettyAaron T ZhaoCynthia L GreenTarannum JaleelPublished in: The British journal of dermatology (2022)
In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.